This is a critical abstract of an economic evaluation that meets the criteria for inclusion on NHS EED. Each abstract contains a brief summary of the methods, the results and conclusions followed by a detailed critical assessment on the reliability of the study and the conclusions drawn.
Interventions
The screening strategies were colonoscopy every 10 years, flexible sigmoidoscopy every five or 10 years, secondgeneration CCE every five or 10 years, FIT every one or two years, and guaiac FOBT every one or two years. Screening was for individuals aged between 50 and 75 years and no screening was also considered.
Location/setting
France/primary care.
Methods

Analytical approach:
The analysis was based on a Markov model, with a lifetime horizon. The authors stated that it was carried out from the perspective of the third-party payer.
Effectiveness data:
The clinical inputs were from published studies, including a European study of FIT screening. Few randomised clinical trials were available and most of the data were from indirect comparisons. The accuracy (sensitivity and specificity) of the screening tests was a key input. Compliance and adherence were assumed to be 100%.
Monetary benefit and utility valuations:
Not considered.
Measure of benefit:
Life-years were the summary benefit measure and they were discounted at an annual rate of 3%.
Cost data:
The economic analysis included the costs of screening, surveillance, and colorectal cancer treatment. The cost of colonoscopy included the assistance of an anaesthesiologist. The costs of screening were from insurance company contracts with the French Association of Physicians. The cost of colorectal cancer was based on a recent published estimate for France. All costs were in Euros (EUR) and a 3% annual discount rate was applied.
